0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Rat Interleukin-1 β Binding Sites in Rat Hypothalamus and Pituitary Gland

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In this study, radiolabeled recombinant rat interleukin-1β (r<sup>125</sup>I-IL-1β) was used to localize and characterize IL-1β binding in rat hypothalamus and pituitary gland by quantitative autoradiography. The ability of this ligand to bind to type I IL· 1 receptor was first tested on murine lymphoma cells (EL-4). In the rat-tissue sections, high densities of specific r<sup>125</sup>I-IL-1β binding sites were localized in the anterior as well as the posterior pituitary and in the choroid plexus. A fine labeling was observed in meninges and third ventricle walls while no binding was detected in the hypothalamic nuclei. Saturation experiments, in the anterior and posterior pituitary, revealed one specific binding site with an affinity constant (K<sub>d</sub>) of 0.5 n M. Competition experiments were achieved using either rat IL-1β (rIL-1β) or human IL-1s (hIL-1α, hIL-1β and IL-1 receptor antagonist: hIL-1α). Affinity constants (Ki) were drastically different according to the ligand used, while K<sub>i</sub> values were found similar in anterior and posterior pituitary. Competition with rIL-1β revealed one binding affinity (K<sub>i</sub> of 0.1 n M range). In contrast, competition with hIL-1β revealed two binding affinities: a high (Ki: 0.1 pM range) and a low one (K<sub>i</sub>: 1 n M range). Competition with hlL-1ra was obtained for high concentrations only (K<sub>i</sub>: 10–100 n M range), whereas human IL-1α (hIL-1α) was unable to compete at 1-100 n M. Therefore, two types of IL·1 binding affinities have been identified in rat pituitary tissues: a very high affinity binding, detected with hIL-1β only and a lower affinity binding. Human IL-1β can therefore be a better ligand for rat receptors than the rat ligand itself while hIL·lα is not. This is suggestive for the existence of several IL-1 receptor subtypes and is in accordance with the biological activity of hIL-1β in the rat. Moreover, the high density of binding sites observed in both anterior and posterior pituitary indicates that pituitary tissues are direct targets for IL-1 stimulation. It is worth noting that IL-1 binding sites cannot be detected in the rat hypothalamus. This raises the question of the mechanism of the hypothalamic IL-1-mediated effects and suggests a role of the third ventricular walls in this mediation.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1995
          1995
          09 April 2008
          : 62
          : 4
          : 362-369
          Affiliations
          aUnit of Pharmacology Neuro-Immuno-Endocrinienne, and bRabies Unit, Pasteur Institute, Paris, France; cResearch Institute Neurosciences, Free University, Medical Faculty, Department of Pharmacology, Amsterdam, The Netherlands; dInstitut de Physique Nucléaire, Paris-Sud University, Orsay, France
          Article
          127026 Neuroendocrinology 1995;62:362–369
          10.1159/000127026
          8544950
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Neuroimmune Interactions

          Comments

          Comment on this article